Margaret Kinney, APRN
Nurse Practitioner · Red Oak, IANPI 1326471517
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,508 of the $13,135 with a category attached, or 72.4%. It is spread thinly across 35 manufacturers, the largest accounting for just 13.0%. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$1K
- Medtronic$1K
- Novartis$1K
- Janssen Research & Development, LLC$1K
- Amgen$700
- plus $5K from 29 others
What the payments were for
- Travel & lodging$3,59327%
- Food & beverage$9,50872%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $1,707 |
| Boston Scientific | 10 | $1,499 |
| Medtronic | 16 | $1,420 |
| Novartis | 102 | $1,345 |
| Janssen Research & Development, LLC | 10 | $1,163 |
| Amgen | 41 | $700 |
| Actelion Pharmaceuticals US, Inc. | 21 | $594 |
| Boehringer Ingelheim | 25 | $567 |
| Pfizer | 38 | $552 |
| E.r. Squibb & Sons, L.L.C. | 17 | $491 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $391 |
| Heartflow, Inc. | 6 | $354 |
| Bayer | 11 | $329 |
| Merck | 17 | $289 |
| AstraZeneca | 10 | $254 |
| Johnson & Johnson | 18 | $227 |
| Impulse Dynamics (USA) Inc. | 4 | $210 |
| Scpharmaceuticals Inc. | 9 | $185 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $127 |
| Bridgebio Pharma, Inc. | 4 | $112 |
| Abiomed | 2 | $96 |
| Esperion Therapeutics, Inc. | 6 | $87 |
| Edwards Lifesciences | 1 | $68 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Atricure, Inc. | 1 | $28 |
| Sanofi | 1 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$1,166
- CARDIOMEMS$1,151
- FFRct$277
- Repatha$230
- UPTRAVI$229
- OPSUMIT$229
- JARDIANCE$226
- SYMPLICITY G3$169
- COREVALVE EVOLUT R$135
- Kerendia$125
- TRICLIP$125
- WATCHMAN Access System$124
- WAINUA$115
How this compares
$13,135 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $147,365 |
| JardianceEmpagliflozin | 125 | $89,962 |
| EntrestoSacubitril/Valsartan | 75 | $58,607 |
| BrilintaTicagrelor | 17 | $9,844 |
| Praluent PenAlirocumab | 14 | $6,676 |
| Midodrine Hcl | 15 | $2,598 |
| Metoprolol Succinate | 217 | $2,564 |
| Atorvastatin Calcium | 186 | $1,578 |
| Potassium Chloride | 117 | $1,567 |
| Torsemide | 84 | $1,203 |
| Furosemide | 173 | $900 |
| Amiodarone Hcl | 63 | $773 |
| Ezetimibe | 36 | $561 |
| Rosuvastatin Calcium | 53 | $560 |
| Flecainide Acetate | 18 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $552 | $147,365171 claims |
| Boehringer IngelheimJardiance | $567 | $89,962125 claims |
| NovartisEntresto | $1,345 | $58,60775 claims |
| AstraZenecaBrilinta | $254 | $9,84417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Red Oak
- Joan SmithRed Oak$3K
- Emily MaassRed Oak$3K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.